Ashling Wahner's profile photo

Ashling Wahner

Bordentown

Assistant Editor at OncLive

Featured in: Favicon onclive.com Favicon newsbreak.com Favicon ajmc.com Favicon cancernetwork.com Favicon curetoday.com Favicon diagnosticimaging.com Favicon targetedonc.com Favicon urologytimes.com Favicon friendsofcancerresearch.org Favicon oncnursingnews.com

Articles

  • Ibrutinib/Lenalidomide/Rituximab Yields Long-Term Efficacy in R/R MCL

    1 week ago | onclive.com | Ashling Wahner

    Ibrutinib (Imbruvica) in combination with lenalidomide (Revlimid) and rituximab (Rituxan; IR2) produced durable responses in patients with relapsed/refractory mantle cell lymphoma (MCL), including initial activity in patients with TP53 mutations, according to long-term follow-up findings from the phase 2 Philemon trial (NCT02460276) published in Hemasphere.

  • Enhanced Dermatologic AE Prophylaxis Is Effective in EGFR-Mutated Advanced NSCLC

    1 week ago | onclive.com | Ashling Wahner

    Prophylactic enhanced dermatologic management significantly reduced the incidence of grade 2 or higher dermatologic adverse effects (AEs) vs standard dermatologic management within the first 12 weeks of first-line amivantamab-vmjw (Rybrevant)/lazertinib (Lacluze) treatment in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), meeting the primary end point of the first preplanned interim analysis of the phase 2 COCOON trial (NCT06120140).1 Findings, which were presented at...

  • Temsirolimus/Metformin Combo Generates Forward-Looking Questions in Endometrial Cancer

    1 week ago | onclive.com | Megan Hollasch |Ashling Wahner

    Each research step that reveals patterns of activity with targeted therapies in endometrial cancer—such as metformin and temsirolimus (Torisel)—brings the field closer to developing increasingly effective and better-tolerated regimens that improve upon historical treatment results and quality of life (QOL) outcomes, according to Pamela T. Soliman, MD, MPH.

  • Multidisciplinary AE Education Enables Safer Inpatient/Outpatient BiTE Therapy

    1 week ago | cancernetwork.com | Ashling Wahner

    According to a study from New York University Langone Health’s Perlmutter Cancer Center, implementing comprehensive patient and health care provider education on bispecific T-cell engager (BiTE) therapy toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and improving multidisciplinary strategies of monitoring patients, has improved the safe administration of these agents in both inpatient and outpatient settings.1 In a...

  • Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma

    1 week ago | onclive.com | Ashling Wahner

    A single infusion of ciltacabtagene autoleucel (cilta-cel; Carvykti) delayed worsening of disease-related symptoms and functional effects in patients with lenalidomide (Revlimid)–refractory multiple myeloma, who also experienced improved quality of life (QOL) over time compared with those who received standard of care (SOC), according to long-term findings from the phase 3 CARTITUDE-4 trial (NCT04181827).1 The findings, which were presented at the 50th Annual Oncology Nursing Society...

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →